HCW Biologics is advancing a pipeline of potentially transformative immunotherapy product candidates for the treatment of inflammaging and age-related diseases. Our initial clinical trials are in the oncology arena, an age-related disease with a high unmet need. We have been cleared by the U.S. Food and Drug Administration to proceed to evaluate our lead drug candidate, HCW9218, in a first-in-human Phase 1b clinical trial in patients with advanced pancreatic cancer. A pair of Phase 2 clinical trials for HCW9201 are now underway for a cell-based therapy treatment for acute myeloid leukemia (AML), through our licensee, Wugen Inc.

Our lead product candidates are undergoing preclinical and clinical development in several indications, including solid and hematologic tumors, such as acute myeloid leukemia (AML), pancreatic cancer, breast cancer and ovarian cancer. Once the safe dose level and regimen of the lead product candidates are defined in the initial clinical trials, HCW will expand into clinical trials for treatments of other age-related pathologies. For HCW9218, these include fibrotic diseases (e.g., NAFLD and liver cancer); and for HCW9302, these include autoimmune and metabolic diseases (e.g., alopecia areata, type 2 diabetes and coronary artery disease).